Insight Molecular Diagnostics (IMDX) Debt to Equity (2020 - 2025)
Historic Debt to Equity for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$0.11.
- Insight Molecular Diagnostics' Debt to Equity fell 28161.87% to -$0.11 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.11, marking a year-over-year decrease of 28161.87%. This contributed to the annual value of -$0.02 for FY2024, which is 11643.09% down from last year.
- Latest data reveals that Insight Molecular Diagnostics reported Debt to Equity of -$0.11 as of Q3 2025, which was down 28161.87% from $0.63 recorded in Q2 2025.
- Insight Molecular Diagnostics' Debt to Equity's 5-year high stood at $0.63 during Q2 2025, with a 5-year trough of -$0.11 in Q3 2025.
- For the 5-year period, Insight Molecular Diagnostics' Debt to Equity averaged around $0.06, with its median value being $0.02 (2021).
- Its Debt to Equity has fluctuated over the past 5 years, first surged by 345675.76% in 2023, then crashed by 28161.87% in 2025.
- Quarter analysis of 5 years shows Insight Molecular Diagnostics' Debt to Equity stood at $0.02 in 2021, then plummeted by 85.07% to $0.0 in 2022, then soared by 3456.76% to $0.11 in 2023, then crashed by 116.43% to -$0.02 in 2024, then plummeted by 518.18% to -$0.11 in 2025.
- Its Debt to Equity was -$0.11 in Q3 2025, compared to $0.63 in Q2 2025 and $0.04 in Q1 2025.